التفاصيل البيبلوغرافية
العنوان: |
A multicenter open-label randomized phase II trial of paclitaxel plus EP-100, a novel LHRH receptor-targeted, membrane-disrupting peptide, versus paclitaxel alone for refractory or recurrent ovarian cancer |
المؤلفون: |
Chelariu-Raicu, Anca, Nick, Alpa, Urban, Renata, Gordinier, Mary, Leuschner, Carola, Bavisotto, Linda, Molin, Graziela Zibetti Dal, Whisnant, John K., Coleman, Robert L. |
المصدر: |
In Gynecologic Oncology February 2021 160(2):418-426 |
قاعدة البيانات: |
ScienceDirect |